Regenerative Medicines Market Trend& Industry Analysis till 2030

The global regenerative medicines market is already an established market. However, emerging submarkets such as cell and gene therapy and stem cell therapy continue to be in a preliminary stage now, anticipating tremendous growth in the short-term. With an increasing number of companies attempting to enter the market with pipelines having high potential, this market will witness tremendous dynamicity. In addition, the growing consolidation in the market is expected to attract more emerging companies to enter the market.

The global market for regenerative medicines generated $21.59 billion in 2019 and is projected to reach the value of $87.03 billion by 2030 with a CAGR of 13.99% during 2020-2030.

Market Segmentation

• Product – Tissue Engineering (Allogeneic Tissue, Autologous Tissue, Xenogeneic Tissue, and Synthetic Tissue), Stem Cells (Stem Cell Services and Stem Cell Therapies), and Cell ang Gene Therapy (Car-T Cell Therapy, Gene Therapy, Other Cell Therapies)

• Application – Orthopedic and Musculoskeletal, Oncology, Wound Care, Cardiology, Immunology, Dermatology, and Other Applications

Regional Segmentation

• North America – U.S., and Canada

• Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

• Latin America – Brazil, Mexico, and Rest-of-Latin America

• Rest-of-the-World

Growth Drivers

• Increasing Consolidation Among Healthcare Juggernauts

• Rising Number of Clinical Trials for Regenerative Therapies

• A Favorable Regulatory Environment to Accelerate Approvals and Market Entry

• A Rising Awareness for Stem Cell Therapeutics

Market Restraints

• Lack of Reliable Vector Production for Cell and Gene Therapy

• Exorbitant Cost of Next-Generation Therapies

Market Opportunities

• Drug Approvals and Strong Pipeline of Cell and Gene Therapies

• Multiple Investments in Expansion of cGMP Units

• Innovations in Regenerative Medicine

Key Companies Profiled

AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.

Request a Sample - https://bisresearch.com/requestsample?id=1092&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Lung Cancer Genomic Testing Market Industry Structure, Development, Demographics, Demands, Main Players, Innovative Technologies, and Opportunities Till 2031

The shift of healthcare systems toward precision diagnostic and precision medicine will drive the adoption of lung cancer genomic testing facilitating informed treatment decision making and improving healthcare outcomes. Increasing recommendations by the international oncology societies for the use of genomic testing for lung cancer diagnosis provides major opportunities in the global lung cancer genomic testing market. The lung cancer genomic testing medicine market was valued at $1,262.0 million in 2020 and is expected to reach $3,279.8 million by 2031, growing at a CAGR of 8.97% during the forecast period 2021-2031. The growth in the global lung cancer genomic testing market is expected to be driven by increasing awareness and adoption of the lung cancer genomic testing market, recent launches of novel lung cancer genomic testing, and the expanding research in the field of lung cancer with an emphasis on pharmacogenomics and development of companion diagnostics. Im...

Ligase Market Opportunities, Strategies, Share, Segmentation, In-depth Analysis 2032

The global ligase market is progressing rapidly with a significant increase in the research and development activities pertaining to a wide range of ligase product for disease detection, accentuating their criticality in healthcare. Ligase enzyme has a critical role in the molecular diagnostics approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the global ligase market offer products encompassing the ligation kits and enzymes. The global ligase market is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development. Impact Several techniques are employed in ...

Market Research Reports

Search This Blog